JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M101278200 on April 25, 2001

J. Biol. Chem., Vol. 276, Issue 30, 27864-27872, July 27, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/30/27864    most recent
M101278200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Preiss, S.
Right arrow Articles by Harley, V. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Preiss, S.
Right arrow Articles by Harley, V. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Compound Effects of Point Mutations Causing Campomelic Dysplasia/Autosomal Sex Reversal upon SOX9 Structure, Nuclear Transport, DNA Binding, and Transcriptional Activation*

Scott Preissabc, Anthony Argentarobc, Andrew Claytond, Anna Johne, David A. Janse, Tsutomu Ogataf, Toshiro Nagaig, Inês Barrosoh, Alan J. Schaferh, and Vincent R. Harleyij

From the a Department of Genetics, University of Melbourne, b Howard Florey Institute, University of Melbourne, Parkville 3052, Australia, the d Department of Molecular Biology, Max Planck Institute for Biophysical Chemistry, Am Fassberg 11D-37077 Goettingen, Germany, the e Division of Biochemistry and Molecular Biology, John Curtin School of Medical Research, Australian National University, Canberra 2061, Australia, the f Department of Paediatrics, Tokyo Electric Power Company Hospital and Keio University School of Medicine, Tokyo 160-0016, Japan, the g Department of Paediatrics, Dokkyo University School of Medicine, Koshigaya Hospital, Koshigaya-shi, 343-8555, Japan, the h Incyte Genomics, 214 Cambridge Science Park, Milton Road, Cambridge CB4 0WA, United Kingdom, and i Prince Henry's Institute, Monash Medical Centre, Melbourne 3168, Victoria, Australia

Received for publication, February 9, 2001, and in revised form, March 20, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Human mutations in the transcription factor SOX9 cause campomelic dysplasia/autosomal sex reversal. Here we identify and characterize two novel heterozygous mutations, F154L and A158T, that substitute conserved "hydrophobic core" amino acids of the high mobility group domain at positions thought to stabilize SOX9 conformation. Circular dichroism studies indicated that both mutations disrupt alpha -helicity within their high mobility group domain, whereas tertiary structure is essentially maintained as judged by fluorescence spectroscopy. In cultured cells, strictly nuclear localization was observed for wild type SOX9 and the F154L mutant; however, the A158T mutant showed a 2-fold reduction in nuclear import efficiency. Importin-beta was demonstrated to be the nuclear transport receptor recognized by SOX9, with both mutant proteins binding importin-beta with wild type affinity. Whereas DNA bending was unaffected, DNA binding was drastically reduced in both mutants (to 5% of wild type activity in F154L, 17% in A158T). Despite this large effect, transcriptional activation in cultured cells was only reduced to 26% in F154L and 62% in A158T of wild type activity, suggesting that a small loss of SOX9 transactivation activity could be sufficient to disrupt proper regulation of target genes during bone and testis formation. Thus, clinically relevant mutations of SOX9 affect protein structure leading to compound effects of reduced nuclear import and reduced DNA binding, the net effect being loss of transcriptional activation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Campomelic dysplasia/autosomal sex reversal (CD/SRA1)1 is a severe skeletal malformation syndrome associated with XY male-to-female sex reversal caused by mutations in the SOX9 gene (1, 2). CD/SRA1 is an autosomal dominant disorder characterized by congenital bowing of the long bones and other skeletal malformations (narrow ilia, hypoplastic ischiopubic rami, micrognathia, cleft palate, and retroglossia), absence of olfactory bulbs and tracts, heart and renal malformations, hypoplastic lungs, narrow thoracic cage, defective tracheobronchial cartilages, small scapulae, and delayed bone age and psychomotor disorders (3, 4). In 75% of cases there is 46 XY testicular dysgenesis (5). The phenotypic changes seen in CD/SRA1 patients correlate with sites of expression of SOX9 and suggest SOX9 is essential for the normal development of many organs. CD/SRA1 individuals are heterozygous resulting in haploinsufficiency of SOX9; presumably a critical dose of SOX9 is required to switch on appropriate genes during development. The present study reports the identification in two CD patients with novel amino acid substitution mutations, A154L and A158T in the HMG domain of SOX9, the latter in an XY female. To understand the functional consequences of these mutations, we attempted to correlate in vitro studies addressing protein structure, DNA binding, DNA bending, and importin recognition with in vivo studies of nuclear transport and transcriptional activation in cultured cells.

SOX9 is a member of a large class of SOX (SRY-type HMG BOX) transcription factors (6) related to the testis determining factor SRY through their HMG domains that bind and bend DNA in a sequence-specific manner (7, 8). Expression of these proteins in certain cell types at specific stages of development appears to govern cell fate decisions. Genes directly regulated by SOX9 have been identified in testis and bone. SOX9 is specifically expressed within testicular Sertoli cells following their differentiation from the supporting cells in the embryonic gonadal ridge (9-11). The sex reversal phenotype of human CD/SRA1 is entirely consistent with a failure of early Sertoli cell differentiation since most sex-reversed patients exhibit normal female phenotype (4). Although the male-determining genes activated by SOX9 in Sertoli cells have not been identified, SOX9 activates the expression of the anti-Müllerian hormone gene (AMH), which leads to the regression of the female reproductive tract (12, 13). SOX9 is also expressed at high levels at all sites where cartilage is being laid down with expression most abundant in mesenchymal condensation just prior to overt chondrocyte differentiation (14, 15). Studies in chondrocyte cell lines and ectopic expression of SOX9 in transgenic mice reveal that SOX9 activates Col2a1 gene, Col11a2, and possibly aggrecan (16-22).

Clinical mutations in SOX9 resulting in CD/SRA1 include splice acceptor/donor changes, missense, nonsense, translocation, and frameshift mutations (4, 23-27). There appears to be no correlation between mutation type or position and severity of the disease or associated sex reversal, with the same mutation causing varying degrees of gonadal dysgenesis (23). Together with the lack of polymorphisms in the SOX9 gene, it appears that SOX9 is intolerant to variation, perhaps acting at a high biochemical threshold which if not reached, CD is manifest. Another possibility is that the genetic background in which the mutant allele resides influences SOX9 activity. The two major classes of mutations causing CD/SRA1 are amino acid substitutions in the HMG domain and truncations or frameshifts that alter the C-terminal domain of SOX9. Two highly conserved domains located at the C terminus, the PQS domain and PQA domain, are required for maximal transcriptional activation, and C-terminal deletions of SOX9 from CD patients show reduced transactivation activity (27). All known point missense in SOX9 occurs in the HMG domain (Fig. 1), the majority of which have been examined biochemically and show altered DNA binding compared with wild type, although there are a few exceptions (23). For example, P170R in the HMG domain had near wild type DNA binding and bending but altered DNA binding specificity (27). A second SOX9 mutant, A119V, showed near wild type DNA binding and bending (27) suggesting that other essential but unknown biochemical activities of the SOX9 HMG domain may exist. These results support a model where reduced HMG domain function will lead to reduced transcriptional activation, although this correlation had not been investigated prior to this study, because previous studies on SOX9 missense mutations in CD/SRA1 have only investigated DNA binding and bending.

The HMG domain consists of three alpha -helices that come together in an L-shape in which the short arm is formed by helices 1 and 2 and the long arm by helix 3 and the N-terminal strand. The concave surface of the "L" contacts the minor groove of the DNA. A number of hydrophobic amino acids from each helix pack together to form a "hydrophobic core" that is thought to stabilize the helices. We previously constructed a model of the SOX9 HMG domain (27), based on the solution structure of the SRY HMG domain, and we observed that most clinical mutations of SOX9 and SRY lie at or near the DNA-binding surface. Here we describe two novel mutations, A154L and A158T, that substitute amino acids within the hydrophobic core and raise the possibility that these residues contribute to the conformation of the HMG domain. Based on our model, these amino acids on helix 3 do not directly bind to DNA, rather they may destabilize the secondary and/or tertiary structure of the HMG domain. This in turn may affect DNA binding and/or DNA bending function of the HMG domain. Also, a signal for nuclear import of SOX9 is located in helix 3 raising the possibility that nuclear import could be affected (28). This nuclear localization signal (NLS) is likely recognized by one of the importins that dock NLS-containing proteins at the nuclear pore complex. We have investigated which components of the nuclear transport machinery normally recognize SOX9 and show that importin-beta strongly interacts with SOX9.

In this study, we examine the structure of the mutant HMG domains by fluorescence spectroscopy and circular dichroism and their ability to bind and bend DNA and to be recognized by importins as part of the nuclear import process. We also examined the effect of these mutations in cultured cells where we measured the ability of SOX9 to transport to the nucleus and to activate transcription. We have demonstrated that both mutants affect protein structure leading to compound effects of reduced nuclear import and reduced DNA binding with consequent reduction of transcriptional activation. Thus, CD/SRA1 arises in these patients from a failure to properly activate transcription of target genes during bone and testis formation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Patients Reports-- Patient 51 was a female infant weighing 3080 g with classic CD. She died 1 day postnatal. The head showed micrognathia, with a small mouth and elongated dome-shaped tongue, flat nasal bridge, mild hypertelorism, and slightly low set ears. There was disproportionate shortness of the limbs most obvious in the lower limbs, which also showed symmetrical anterior bowing of the tibiae, pretibial dimples, and talipes equinovarus. There was a cleft palate involving the soft and posterior part of the hard palate. The heart was not enlarged and showed atrial situs solitus with concordant atrioventricular and ventriculo-arterial connections. There was bowing of both femora and tibia convexed laterally. Epiphyseal centers for the lower end of the femur and upper end of the tibiae were absent. The tibia showed anterior bowing at the junction of the middle and lower third of the shaft, and there were bilaterally dislocated hips and abnormal ischial bones. There was a delay in ossification of the epiphyseal centers, diagnostic of campomelic dwarfism. The presence of ovarian tissue was confirmed, and numerous germ cells were seen. The long bones showed abnormal ossification with some irregularity of endochondral ossification. The cortical bone on the posterior aspect of the shaft was thickened.

Patient 61 is a 46, XY female with a milder form of CD. At present, she is 19 years of age and is assisted with mechanical ventilation. This patient was born to healthy non-consanguineous parents at 39 weeks of gestation. Physical examination showed flat face with prominent forehead, cleft palate, and clubfeet. Bone survey revealed bowing of the femurs and tibia, as well as slim, poorly developed bones and osseous immaturity. External genitalia were feminized with mild clitoromegaly. At 2 years of age, a human chorionic gonadotropin test yielded no testosterone response, and a human menopause gonadotropin test gave no estradiol response. A gonadotropin-releasing hormone test showed hyperresponses of luteinizing hormone (7.2 right-arrow 66.5 IU/liter) and follicle-stimulating hormone (11.3 right-arrow 80.2 IU/liter).

Polymerase Chain Reaction Amplification, SSCP, and DNA Sequencing-- To screen for the mutation, the entire SOX9 open reading frame was amplified from genomic DNA from blood lymphocytes by polymerase chain reaction and analyzed by SSCP as described previously (24).

Molecular Modeling-- Homology modeling was used to generate model structures of SOX9 using the NMR structure of SRY as described previously (27). Molecules were rendered using the Molecular Simulations Inc. software WebLabViewer.

Mutagenesis-- The CD mutations were introduced into SOX9 using the pAlter Mutagenesis kit (Promega) according to the manufacturer's instructions using the following oligonucleotides: F154L, 5'-AGCGGGAGGCGAGAAGCGgCCCTTGGTGGAGAG-3'; A158T, 5'-CGCCCCTTCGTGGAGGAGACGGAGCGGCTGCGCGTGCAG-3'. pAlter-SOX9 was subsequently digested with EcoRI and XhoI, and the mutant cDNAs were subcloned between the EcoRI and XhoI sites in pcDNA3 for transient transfection in cultured cells and in vitro production of protein. pAlterSOX9 mutants were also digested with BssHII and SacII, and the 125-base pair fragment was inserted into the BssHI/SacII sites in the pT7SOX9HMGbox expression plasmid (27).

Production of Mutant and Wild Type SOX9 HMG Domains-- Recombinant SOX9 HMG protein (amino acids 101-184) was expressed and purified from Escherichia coli as described (29) with a modification to the protocol whereby SOX9 HMG protein was extracted by sonication from PBS-washed cell pellets in 100 ml of HEDA buffer (50 mM HEPES, pH 7.9, 1 mM dithiothreitol, 1 mM EDTA, 50 µM 4-(2-aminoethyl)benzenesulfonyl fluoride). The sample was then brought to a final concentration of 450 mM NaCl and mixed with a 0.1 volume of 50% DEAE-Sephadex equilibrated in HEDA buffer, 450 mM NaCl for 10 min at 4 °C. Following centrifugation (Sorvall RC5B, GS3 rotor; 6000 × g, 10 min, 4 °C), the salt concentration of the supernatant was reduced to <0.2 M by diluting the sample volume 2.5-fold with HEDA buffer, and the supernatant was filtered, under pressure, through a 0.45-µm membrane. The sample was injected onto a 10-ml SP-Sepharose column pre-equilibrated in HEDA buffer containing 200 mM NaCl. Bound proteins were eluted over 40 min with a salt gradient of HEDA buffer containing 200-1000 mM NaCl, and 5-ml fractions were collected. SOX9 HMG elutes at about 0.7 M NaCl containing fractions >90% SOX9 HMG protein. SOX9 HMG protein was desalted and concentrated using Amicron Centriprep 3 cartridges. Protein concentrations were determined against Bradford assay reagent kit (Bio-Rad) with bovine serum albumin as a standard.

Tryptophan Fluorescence Spectroscopy-- Fluorescence spectra were recorded on a SPEX Fluorolog-tau 2 frequency domain spectrofluorometer. Excitation of tryptophan was accomplished using vertically polarized light at 295 nm from a 450-watt xenon lamp. The emission was observed through a polarizer oriented at the magic angle (54.7o), and spectra were measured in the wavelength range of 300-500 nm. The spectral band pass of excitation and emission was 5 nm. 500-µl cuvettes were used with a protein concentration of 2 µM. Spectra were fully corrected for the wavelength response of the detection system. The cell block was maintained at 20 °C with a circulating water bath (30, 31).

Acrylamide quenching was performed using an excitation wavelength of 295 nm to avoid tyrosine excitation and distortion by acrylamide. 10-µl aliquots of 4 M acrylamide were added successively to 400 µl of a 2 µM protein sample, and the fluorescence intensity was recorded at 350 nm with a PerkinElmer Life Science LS-5 spectrofluorometer. The fluorescence was corrected for dilution and inner-filtering by acrylamide (30, 32).

Circular Dichroism Spectroscopy-- The circular dichroism of SOX-9 and its mutants were recorded at 222 nm using an AVIV model 62DS spectrometer with a spectral bandwidth of 2 nm. The sample temperature was controlled electronically with a Peltier device.

Production of Mutant and Wild Type Full-length SOX9-- Full-length SOX9 protein was produced in vitro by coupled transcription and translation of SOX9 (wild type and mutants) in pcDNA3, using a TNT kit (Promega), with incorporation of [alpha -35S]methionine.

Cell Types and Culture and Transient Transfections-- COS-7 cells were cultured as a monolayer in RPMI 1640, supplemented with 1% (v/v) penicillin/streptomycin, 1% L-glutamine, and 10% (v/v) fetal calf serum, at 37 °C under 5% CO2.

COS-7 cells were transfected by DEAE-dextran-assisted electroporation (33). Transactivation by SOX9 was measured in transfection assays, using the reporter plasmid, pS10E1bCAT, in which the CAT gene is under the control of the E1b promoter, downstream of 10 SOX core-binding sites (AACAAT). Cells (1 × 106) in log growth phase were transfected with 1 µg of pS10 E1bCAT, 26 ng of pcDNA3 or pcDNA3-SOX9 (wild type or mutant), and 20 ng of pCMV-lac, in a volume of 600 ml of RPMI 1640 containing 10 mg/ml DEAE-dextran. Pulse conditions were 960 microfarads and 250 mV using a Gene Pulser apparatus (Bio-Rad). Cells from each transfection were seeded into two flasks after addition of 6 ml of RPMI and were grown for 48 h before being harvested. Protein concentrations, in cell lysates, were determined by Bradford assay. CAT expression was determined by enzyme-linked immunosorbent assay, using a CAT enzyme-linked immunosorbent assay kit (Roche Molecular Biochemicals). To correct for varying transfection efficiencies, beta -galactosidase levels were assayed, and CAT levels were normalized for beta -galactosidase expression. beta -Galactosidase expression was assayed using the beta -galactosidase enzyme assay system (Promega).

Immunohistochemistry-- COS-7 cells were transiently transfected with pcDNA3-SOX9 or mutant using LipofectAMINE (Life Technologies, Inc.) according to the manufacturer's instructions. For SOX9 staining, COS-7 cells grown in 8-well Chamber slides (Nunc) were fixed in 5% paraformaldehyde/PBS for 30 min at room temperature and permeabilized with 0.5% Triton X-100 (ICN) in PBS for 5 min at room temperature. Cells were than incubated for 30 min with goat or horse serum in a humidified atmosphere. Cells were than incubated with specific polyclonal antibody anti-SOX9 (9) or anti-hemagglutinin (HA) antibody. Slides were washed three times (5 min each) in PBS and incubated for 90 min at room temperature with fluorescein-conjugated anti-rabbit antibody (dilution 1:500, anti-SOX9 from Sigma) or fluorescein-conjugated anti-mouse antibody, dilution 1:500 (anti-HA from Sigma). After three washes in PBS, coverslips were mounted in glass slides with buffered glycerol (containing 1:2000 dilution of TO-PRO3 (Molecular Probes) to detect nuclei of cells) and viewed under the Leica fluorescence microscope using a fluorescein isothiocyanate filter, rhodamine filter, or both. Cells were photographed using slide film (Eastman Kodak Co.) in a camera (Leica) at × 20 and 40 magnification. Quantitation of nuclear import, confocal laser scanning microscopy (MRC-500, Bio-Rad) was performed as described (34).

Importin ELISA-binding Assays-- An ELISA-based assay was used to examine the binding affinities of mouse importin-alpha and importin-beta -glutathione S-transferase (GST) fusion proteins as described previously (34). 96-Well microtiter plates were coated with bacterially expressed and purified HMG domains and incubated overnight at 4 °C. After blocking with bovine serum albumin, the protein was hybridized to increasing amounts of importin-alpha -GST, importin-beta -GST, or precomplexed importin-alpha /beta -GST and incubated for 16 h at 4 °C. Bound importin was detected using goat anti-GST and anti-goat IgG, alkaline phosphatase-conjugated antibodies. After the addition of the colorimetric substrate p-nitrophenyl phosphate, A405 was measured at 5-min intervals for 90 min using a microplate reader (Molecular devices, Sunnyvale, CA), and values were corrected by subtracting absorbances both at 0 min and in wells incubated without importin.

Electrophoretic Mobility Shift Assays-- Oligonucleotide probes were synthesized on an Applied Biosystems 394 DNA/RNA synthesizer. The sequences of the upper strands are given below. S9WT sequence is GGGTTAACAGAACAATGGAATCTGGTAGA. The high affinity SOX9-binding site is shown in bold. It consists of the high affinity SOX-binding site (SOXCON) flanked by four residues that enhance binding of SOX9 (underlined) (29). To prepare probes, complementary oligonucleotides were annealed and radiolabeled by end-filling with Superscript reverse transcriptase in the presence of [alpha -32P]dCTP and purified on Bio-Gel P4 spin columns. E. coli cell lysates containing SOX9 HMG domain (0.25 nM) were mixed with alpha -32P-labeled probe in a total volume of 16 ml of binding buffer (35) and kept on ice for 15 min before electrophoresis. Protein-DNA complexes were resolved from free DNA on non-denaturing 6% polyacrylamide gels (40:1 (w/w) acrylamide/bisacrylamide) in 0.5 × TBE for 3.5 h at 10 V/cm. Prior to sample loading, the gel was pre-run for 2 h at 150 V. Shifted and free probe was quantitated by PhosphorImager analysis.

Circular Permutation Assay-- Pairs of oligonucleotides bearing SOXCON (GGGTTAACAGAACAATGGAATCTGGTAGA) were annealed to its complement oligonucleotide. The SOX9 high affinity-binding site is shown in bold. pBEND2-SOXCON was created by insertion of these linkers between the XbaI and SalI sites of pBEND2 (36). Six circularly permuted probes bearing the binding sites were isolated by digestion of these plasmids with BglII (A), ClaI (B), XhoI (C), EcoRV (D), StuI (E), and BamHI (F) and excision of the bands after agarose gel electrophoresis. The probes were then treated with shrimp alkaline phosphatase and labeled with [alpha -32P]ATP using T4 polynucleotide kinase. Probes (0.2-0.8 ng) were mixed with extract containing 0.2 µg of wild type ~2 µg of mutant SOX9 HMG domain in binding buffer (35), in a total volume of 16 µl, and kept for 20 min on ice. Products were resolved by electrophoresis through 6.5% polyacrylamide non-denaturing gels (40:1 (w/w) acrylamide/bisacrylamide) as described above. Bend parameters were calculated as described previously (37). Gels were exposed to PhosphorImaging plates and developed on a Fujix Bas 2000.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Detection of Novel SOX9 Mutations in Two CD Patients-- Analysis of the SOX9 open reading frame from two CD/SRA1 patients using SSCP and subsequent DNA sequencing identified two novel missense mutations (F154L and A158T) in the SOX9 HMG domain from two patients (Fig. 1A; see Table I for details). Both patients carried the mutation on one allele only, the other showing wild type DNA sequence, indicating that the mutations were heterozygous.


View larger version (67K):
[in this window]
[in a new window]
 
Fig. 1.   Detection of two novel SOX9 mutations in patients with CD/SRA1. A, SSCP assay of DNA from patients 51 and 61; in each case the band that differs between the mutant and wild type alleles is indicated with an arrow. Controls include DNA amplified from two normal individuals. DNA sequence analysis of the abnormally migrating bands shows the codon change TTC to TTG specifying a Phe154 to Leu amino acid substitution in patient 51 and codon change GCG to ACG specifying a Ala158 to Thr amino acid substitution in patient 61. B, diagram of the entire SOX9 open reading frame showing the different domains of the protein and the missense mutations that have been identified in patients with CD. SOX9 is a 509-amino acid-long protein that has three notable features as follows: an HMG box 100 amino acids from the N terminus; a PQA (residues 339-379); and a PQS-rich (residues 386-509) domain at the C terminus of the protein. Mutations identified in XY females (i.e. showing autosomal sex reversal, SRA1 phenotype) are indicated as circles below and those in XX females (F) or XY males (M) above. Mutations investigated in the present study are indicated with filled circles. C, the HMG box of SOX9 is an 80-amino acid DNA binding domain, consisting of three alpha -helices that form an L-conformation. The HMG box has a highly hydrophobic core formed by amino acids mainly on the first and second helix, and this core maintains the angles between the helices. The hydrophobic core is believed to be maintained by the orthogonal packing of 11 amino acids, mainly on helix 1 and 2 with contributions from Phe154 and Ala158 (underlined) from helix 3. This representation of SOX9 HMG is in a DNA-bound conformation showing the DNA severely bent and unwound by SOX9. The atomic coordinates (code BNL-27758 for the model of the wild type SOX9 HMG domain model are available in the Protein Data Bank, Research laboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ). D, an amino acid sequence alignment of SOX9 HMG domain with selected SOX proteins, representing each subgroup, showing high conservation of both Phe154 and Ala158 positions. Regions shaded show the N- and C-terminal nuclear localization signals. Boxed regions correspond to the positions of the three helices and loops of the SOX9 HMG domain.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Missense CD mutations analyzed in this study
Numbering of nucleotide (nt) and amino acid positions are according to Ref. 2.

Structure of SOX9 HMG Domain-- According to our model of SOX9 HMG domain (27), the F154L and A158T mutations substitute amino acids on helix 3, which are predicted to be involved in maintaining the hydrophobic core as both protrude into it (Fig. 1C). In addition, amino acid sequence alignments of SOX9 HMG domain with SOX of other groups show that amino acids 154 and 158 are highly conserved (Fig. 1D). Thus, it is possible that F154L and A158T mutations destabilize the hydrophobic core and alter the relationship between the second and third helix leading to perturbations in the structure of the SOX9 HMG box that may alter its biochemical properties.

Fluorescence Properties-- Changes in tryptophan fluorescence from proteins are sensitive to the environment about the indole chromophore and can provide information concerning changes in protein structure and dynamics. We have shown previously that the fluorescence from the HMG domain of SRY is sensitive to changes in local environment about the tryptophan residues and undergoes shifts to distinct wavelength and emission maximum upon DNA binding or calmodulin binding when compared with the free HMG domain (31). Therefore, we measured the tryptophan fluorescence of wild type and mutant SOX9 HMG domains. SOX9 HMG domains were expressed in E. coli bacteria and purified by ion exchange chromatography to approximately >90% purity by SDS-PAGE analysis (Fig. 2A). Table II shows a comparison of three fluorescence parameters that report on the tryptophan micropolarity (wavelength maximum), the tryptophan dynamics (anisotropy), and the accessibility to solvent (acrylamide accessibility). The physical extremes of these parameters correspond to tryptophan environments that range from being non-polar to polar (320-330 to 355 nm), mobile to immobile (<0.05 to 0.24), and accessible to shielded (25 to <1 M-1), respectively. Table II shows that the SOX9 HMG tryptophan fluorescence is characterized by a relatively non-polar environment (340 nm), a moderate accessibility to acrylamide (10 M-1), and is restricted in its mobility (0.125). The A158T mutation produces no detectable alteration in the micropolarity or mobility of the tryptophan residues, and a 10% decrease in accessibility to acrylamide compared with wild type (a 4% change compared with fully accessible/shielded). The F154L mutation changes all three tryptophan fluorescence parameters. Compared with the wild type protein, the tryptophan micropolarity (339 nm) and mobility (0.131) undergo a slight decrease, whereas the accessibility to acrylamide increases (11 M-1). As for the A158T mutation, the change in these parameters represents a fractional change of less than 5% compared with the full range of parameter space.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Circular dichroism analysis of normal and mutant HMG domain structure. A, SDS-PAGE analysis of E. coli recombinant wild type (WT) and mutant SOX9 HMG domains produced in E. coli. Cell lysates before (-) and after (+) ion exchange chromatography were resolved on a 10-20% polyacrylamide gradient gel at 20 V/cm for 180 min and stained with Coomassie Brilliant Blue. The position of the SOX9 HMG domain and molecular size markers in kilodaltons are indicated on the left. B, the temperature dependence of the relative ellipticity at 222 nm of SOX9 HMG domains (filled circles) and SOX9 mutants, A158T (unfilled squares), F154L (filled squares). C, thermal denaturation curves of SOX9 and mutants. The apparent fraction unfolded protein is plotted against temperature. Symbols as for Fig. 2B.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Tryptophan fluorescence parameters of SOX9 and single substitution mutants

Circular Dichroism-- The circular dichroism ellipticity at 222 nm is often used as an indicator of helicity in proteins and, when combined with measurements over a range of temperatures, can yield insight into protein conformational and thermal stability. Table III summarizes the relative CD at 222 nm of wild type and mutant SOX9 HMG domain over a range of temperatures. Fig. 2B shows the corresponding thermal melt curves. Two points are of particular note. First, mutations of the SOX9 HMG domain cause a decrease in the level of (helical) secondary structure at all temperatures investigated, as indicated by the increased ellipticity at 222 nm of both A158T and F154L, compared with the wild type protein. Second, the CD melt curves of all three proteins, when normalized to an apparent fraction unfolded scale, are superimposable which implies their folded domains have similar stabilities to heat denaturation over the temperatures studied (Fig. 2B).

                              
View this table:
[in this window]
[in a new window]
 
Table III
Thermal stability and helicity of SOX9 and mutants

Nuclear Import and Recognition of SOX9 by Importins-- To investigate the properties of mutant SOX9 in cultured cells, mammalian expression plasmids encoding wild type and mutant full-length SOX9 were constructed. SDS-PAGE analysis shows that the full-length mutant SOX9 proteins were translated efficiently from pcDNA3 plasmids in rabbit reticulocyte lysate system (Fig. 3A). SOX9 carries signals for nuclear import at each end of its HMG domain (28). NLSs tend to be amphipathic helices, and so the function of the SOX9 NLSs could be perturbed by structural changes (loss of helicity) in the HMG domain. To assess the effect of SOX9 mutations upon nuclear import, full-length wild type and mutant SOX9 plasmids were transiently transfected into COS-7 cells, and the subcellular localization of SOX9 was determined 24 h after transfection using indirect immunofluorescence and confocal laser scanning microscopy and quantitated using image analysis (Fig. 3B). Wild type SOX9 efficiently accumulated in the nucleus (ratio of accumulation of SOX9 fluorescence in the nucleus relative to the cytoplasm - Fn/c of 30) as did the F154L mutant, but the F158T mutant showed a significant (p = 0.0316) reduction of nuclear accumulation of approximately 2-fold (Fn/c of 13).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 3.   Nuclear accumulation and importin binding of full-length wild type and mutant SOX9. A, autoradiography of SDS-PAGE of wild type and missense mutations of SOX9 expressed in vitro in rabbit reticulocyte lysate. Molecular size markers in kilodaltons are indicated on the left. B, plasmids for mammalian cell expression of hemagglutinin (HA) epitope-tagged SOX9, pcDNA3-HA-SOX9, pcDNA3-HA-SOX9A158T and pcDNA3-HA-SOX9F154L were transfected into COS-7 and SOX9 protein detected by indirect immunofluorescence, using rabbit anti-HA as the first antibody and fluorescein isothiocyanate-conjugated goat anti-rabbit antibody as the second antibody. Fn/c refers to the ratio between nuclear (Fn) and cytoplasmic fluorescence (Fc). Each point represents the average of greater than 19 separate measurements of each of Fn, Fc, and autofluorescence. A one-way analysis of variance revealed a significant difference between the mean Fn/c values for wild type and the A158T mutant, p < 0.032. C, Binding curves of SOX9 HMG domains with importins. ELISA microtiter plates were coated with SOX9 HMG box or mutant as indicated and incubated with increasing concentrations of mouse importin subunits. Data are fitted for the function B(x) = Bmax (1 - e-kB), where x is the concentrations of importin and B is the amount of importin bound. The results are from a single experiment performed in triplicate (see Table IV for Kd values, representing the importin concentration yielding half-maximal binding, from pooled data).

NLSs are conventionally recognized by the nuclear import receptor, a heterodimer of importin (karyopherin)-alpha /beta subunits (see Ref. 38 for review). The HMG domain of SRY is recognized directly by importin-beta , independently of importin-alpha , via the NLS at the C-terminal end of helix 3.2 This NLS sequence is highly conserved in all SOX proteins, so it seemed likely that importin-beta would interact with SOX9. To test this possibility, we investigated, by ELISA, the interaction of the SOX9 HMG box with importin-alpha , importin-beta , and the heterodimer importin-alpha /beta . SOX9 HMG domain is recognized more strongly by importin-beta (Kd of 1.7) compared with importin-alpha (55 nM) (Fig. 3C; Table IV) consistent with the results obtained for SRY.2 No significant differences in importin-beta binding were detected for the SOX9 mutants compared with wild type SOX9 HMG box suggesting that the decrease in nuclear accumulation of mutant A158T is not due to defects in importin-beta binding (Fig. 3C).

                              
View this table:
[in this window]
[in a new window]
 
Table IV
NLS binding parameters of SOX9 derivatives as measured using an ELISA-based binding assay
Importin binding parameters were determined as described under "Experimental Procedures" (34) from experimental data fitted as shown in Fig. 3C. Results for the apparent dissociation constant (Kd) and maximal level of binding (expressed as a percentage relative to the binding of mlmp alpha /beta to SOX9 wt represent the mean ± S.E.M. (n in parentheses).

DNA Binding and DNA Bending-- SOX9 encoded by some CD patients showed reduced DNA binding activity consistent with the DNA binding ability of SOX9 being essential for its function as a transcription factor. The ability of the mutants to bind DNA, relative to wild type, was measured. DNA concentrations were varied, and SOX9-bound versus free DNA was quantitated from electrophoretic mobility shift gels (Fig. 4A) (29). DNA probe SOX9CON bears the high affinity SOX9-binding site selected in vitro (AGAACAATGG) which consists of SOX consensus motif (A/T)(A/T)CAA(A/T) flanked on either side by the two bases specifically preferred by SOX9 (29). The dissociation constant (Kd) was calculated for wild type and mutant SOX9-DNA complexes, and Scatchard plots were drawn (Fig. 4B; Table V). Wild type SOX9 HMG gave a Kd of 12.6 nM, consistent with the published value of 12.4 nM (29). F154L by comparison gave Kd of 244 nM, a reduction to 5% of wild type SOX9 DNA binding affinity. A158T is less affected with a Kd of 76 nM, a reduction to 16.6% of wild type SOX9 DNA binding affinity.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 4.   Scatchard analysis of the equilibrium DNA binding of wild type and mutant SOX9 HMG domains. A, binding reactions containing a fixed amount of SOX9 HMG domain (0.25 nM) and increasing concentrations of DNA probe (10-150 nM, right to left) were resolved by non-denaturing gel electrophoresis and bound and free DNA probe quantitated from three experiments performed in duplicate. An electrophoretic mobility shift assay is representative of one experiment shown. B, Scatchard analysis of the equilibrium binding of SOX9 HMG domain to DNA probe SOX9CON. The points plotted are the mean of duplicate data points from one experiment, see Table V for pooled data.

                              
View this table:
[in this window]
[in a new window]
 
Table V
DNA binding activity of wild type and mutant SOX9

Certain point mutations in the HMG domain of SRY in patients with XY gonadal dysgenesis alter the DNA bending properties of the protein (8). Since DNA bending is also likely to be important for SOX9 function, we set out to determine the bend angles induced upon binding of the wild type and mutant HMG domains to SOX9CON DNA probe. A circular permutation assay was used to determine the bend angle induced by SOX9 HMG (Fig. 5). Wild type deflected the linear DNA probe SOX9CON by 59 ± 0.5°. Differences between our results and those published (39-41) could be due to slight differences in assay conditions, as have been observed for SRY. Both the mutants and wild type SOX9 show no significant differences in their ability to bend DNA with both mutants also bending DNA 59 ± 0.5° from linearity. Thus, the F154L and A158T mutations did not appear to alter the DNA bending properties of SOX9.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 5.   DNA bending by wild type and F154L or A158T mutant HMG domains. Circularly permutated probes were labeled with 32P and incubated with ~0.2 µg of F154L, 0.2 µg of A158T HMG domain, or 0.02 µg of wild type HMG domain. Bend angles were estimated as described previously (48). The probe names (A (BglII), B (ClaI), C (XhoI), D (EcoRV), E (StuI), and G (BamHI)) relate to the position of the SOX-binding site following restriction digestion of a linear DNA fragment shown at top comprising a tandem multiple cloning site with a central SOX9 DNA-binding site (30).

Transactivation Properties in Cultured Cells-- In order to determine whether the two mutations SOX9F154L and SOX9A158T had altered transcriptional activity, pcDNA3-SOX9F154L and pcDNA3-SOX9A158T plasmids were transiently transfected with pS10E1bCAT into COS-7 cells. Transcriptional activity of both mutant proteins was significantly lower than wild type SOX9. In COS-7 cells transfected with the reporter construct pS10E1bCAT and pcDNA3-SOX9F154L, expression of the CAT reporter gene was 26% of wild type SOX9 activity (Fig. 6). In COS-7 cells transfected with the reporter construct and pcDNA3-SOX9A158T, expression of the CAT reporter gene was 62% of wild type SOX9 (Fig. 6; Table VI). Quantities of SOX9-transfected plasmids were in the linear response range (data not shown).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 6.   Transactivation of full-length wild type and mutant SOX9. Transcriptional activity of SOX9 and mutants was measured by determination of CAT expression in lysates of COS-7 cells co-transfected with pcDNA3-SOX9 (and missense mutants) and the reporter plasmid pS10E1bCAT. pCMV-lac was co-transfected, and beta -galactosidase activity was assayed to account for variations in transfection efficiency. A one-way analysis of variance revealed a significant difference between the mean levels of CAT/unit beta -galactosidase for the different DNA constructs (F (2, 15) = 22.962, p < 0.001). Comparison with wild type SOX9 shows a significant decrease in transcriptional activity for both mutants (**, p < 0.01; ***, p < 0.001).

                              
View this table:
[in this window]
[in a new window]
 
Table VI
Transactivation of wild type and mutant SOX9


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we report the identification of the novel amino acid substitution mutations F154L and A158T in the SOX9 HMG domain of two patients with campomelic dysplasia, the former an XX female and the latter a sex-reversed XY female. Fig. 1B shows the positions of these substitutions on the SOX9 open reading frame together with those of previously reported mutations. Apart from the fact that all known missense mutations occur in the HMG domain, no correlation seems to be emerging between the position of the mutations and their clinical severity and associated sex reversal.

Based upon our molecular model of SOX9 (27), we postulated that Phe154 and Ala158 form part of a hydrophobic core region and would play a role in stabilizing the three-dimensional alignment of the three helices of the HMG domain. The substitution of a phenylalanine by a leucine in mutant F154L may have several consequences including an alteration of hydrophobic packing due to the replacement of a bulkier amino acid by a smaller one (39), a loss of aromatic-aromatic interactions (40-43), or a decrease in helicity due to alterations of phenylalanine-side chain interactions between amino acids proximal to helix 3 (44). The replacement of an alanine by a threonine in mutant A158T substitutes a small non-polar amino acid for a big relatively non-polar amino acid and thus would be expected to affect hydrophobic interactions in this region of the protein. However, the fluorescence studies did not demonstrate significant changes in tertiary structure. The mutations would appear not to perturb the environment or tertiary structure (relative orientation of the helices) as probed by the tryptophan residues of the hydrophobic core, nor does it affect the stability of the (residual) folded structure of the mutants as compared with the wild type protein. This could suggest functional redundancy in amino acids that form the hydrophobic core.

In contrast, our circular dichroism results suggest that the main effect of mutation at Phe154 and Ala158 is upon loss of secondary structure, mainly in helix 3. Both SOX9 mutations are located close to helix 1/helix 2 tryptophan residues. In the related Sox5 protein, the concept of "multidomain unfolding" has been explored whereby unfolding of helix 1/helix 2 arm leads to large (15 nm) changes in tryptophan fluorescence (45). Thus a complete loss of structure in the helix 1/helix 2 wing is an unlikely consequence of the mutations since the tryptophan fluorescence properties of the two mutant SOX9 proteins are largely unaffected, but small changes could be through "local effects" of the substitutions. This leaves the possibility that helix 3 itself is perturbed in local structure. Threonine is known to cause loss of secondary structure (46) and to bend alpha -helices (47). Furthermore, thermally induced unfolding of helix 3 as a separate domain from helix 1 and helix 2 has been observed in the HMG domain of Sox5 (45).

Helix 3 of the SOX9 HMG domain possesses a functional NLS, as does helix 1 (28) (Fig. 1D). We show that SOX9 is recognized by the nuclear transport receptor importin-beta and not by the more widely reported NLS receptor, importin-alpha . Given that the NLSs are highly conserved among SOX proteins (shaded in Fig. 1D), we predict that all SOX proteins utilize an importin-beta -mediated nuclear import pathway. The NLS located at the end of helix 3 is a conventional basic amphipathic helix which, in SRY, mediates nuclear import via direct interaction with importin-beta .2 In SOX9, the A158T mutant showed decreased nuclear accumulation. This mutation is more proximal to the helix 3 NLS than F154L (whose nuclear import was normal) and might disrupt the function of this NLS. However, A158T bound with wild type affinity to importin-beta suggesting that while this recognition step is normal, other components of the importin-beta -mediated nuclear import pathway could be affected. Alternatively, the A158T mutation could indirectly affect the function of the helix 1 NLS, whose import mechanism has not been defined, but may involve calmodulin which has been implicated in import and which recognizes helix 1 of SRY (31). The two NLSs appear to be able to function independently but are close together in three-dimensional space, and the dramatic conformational changes to SRY HMG domain that occur upon calmodulin binding might regulate NLS activity. Further studies are also required to elucidate the component of nuclear import that presumably fails to recognize efficiently the A158T mutant. The demonstration here that a mutation outside the NLS regions affects nuclear localization raises the possibility that a large number of SRY, SOX9, and SOX10 clinical mutations could affect nuclear import in addition to, or distinct from, DNA binding and bending. In support of this, SRY mutation R62G, a mutation outside the helix 3 NLS, showed decreased nuclear accumulation and reduced importin-beta binding.2

Substitutions at the two positions in SOX9 studied here have also been reported at the corresponding positions in the HMG domain of SRY in two XY gonadal dysgenesis patients. The first example is SRY-A113T, analogous to SOX9-A158T, which showed reduced DNA binding like the SOX9-A158T mutant but also showed altered DNA bending (48).3 This suggests that altering the secondary structure in this region of the HMG domain of SRY and SOX9 (which show 70% amino acid similarity) has different consequences. Thus DNA bending by wild type SRY and SOX9 HMG domains is not identical, despite their ability to bend DNA of the same sequence to the same angle (27, 29). Key determinants of DNA bending appear to reside on helix 1 consistent with the observation that helix 1/2 is unperturbed and DNA bending is normal in both SOX9 mutants in this study. Helix 1/2 wing contributes two key helix 1 amino acids, Met111 (Ile68 in SRY), which acts as a wedge intercalator and adjacent Met107 (Met64 in SRY; two sex-reversing SRY mutations at Met64 alter bend angle (8)),3 which interacts with the DNA backbone at the site of the bend. The second example is the SRY-F109S substitution in an XY gonadal dysgenesis patient, which corresponds to SOX9-F154L and is a familial mutation inherited by the fertile father (49). The structure of SRY shows that the Phe109 is buried within the hydrophobic core and packs against Ala111, Val114, and Trp115 of helix 1 and Phe155 of helix 2 (SOX9 numbering; Fig. 1C) and might be expected to affect protein stability. Although SRY-F109S protein showed no significant change in DNA binding affinity compared with wild type (49), the substitution of Phe for Leu in SOX9 caused a 20-fold reduction in DNA binding. The simplest explanation is that serine substitution would be less disruptive to the hydrophobic core than leucine substitution in either context.

This study presents data for the first time on the effect of point mutations in CD upon transactivation activity in cultured cells and allows us to correlate this with DNA binding activity in vitro. In the A158T mutant, a 6-fold loss of DNA binding activity together with a 2-fold loss of nuclear import led to only a 26% loss of transcriptional activation. Similarly, in the F154L mutant, a 20-fold loss of DNA binding activity led to only a 62% loss of transcriptional activation activity. Our binary in vitro system is simplistic given that SOX9 acts in the context of a multiprotein complex in vivo. During testis formation, SOX9-SF1 and WT1-SF1 are required on the MIS promoter (11), and the Sox5/Sox6 heterodimers are required for maximal activation of the Col2a1 promoter (18). Furthermore, reduced DNA binding affinity may still permit transient occupancy of a SOX9-binding site by SOX9 in vivo at levels sufficient to activate transcription once bound, provided the correct DNA architecture is established (50, 51). Also, it might be that other functions of the HMG domain, for example interactions with co-activators, are at play. Our data are consistent with that for yeast ROX1, the only other HMG domain protein for which in vitro/in vivo correlations have been reported. In ROX1, substitutions causing a large reduction in DNA binding activity in vitro produce a small effect upon ANB1 repressor activity in vivo (52). For example the analogous change to SOX9 A158T in ROX1 affects DNA binding 10-fold and repression in vivo 4-fold. In ROX1 Phe154 is Trp and a substitution to Leu affects DNA binding 1000-fold but repression only 50-fold. Thus a reduction in DNA binding in vitro produces only a small effect in vivo, but this is presumably sufficient to account for the phenotypic effects. On this basis, small changes in DNA binding activity of SOX9 mutants may show undetectable changes in transactivation and lead to wild type phenotype. In SRY, small changes in DNA binding activity with partial penetrance of SRY were observed to occur in familial cases, i.e. when a weak allele is inherited by a fertile father (7, 49). However small changes in SOX9 DNA binding activity in vitro do not seem to correlate with milder symptoms, in these cases it could be that alterations of non-DNA binding functions of the HMG domain underlie the defect. Our data show that A154T mutant has 62% of wild type activation function in cultured cells. Given that this observation reflects the situation in vivo in CD/SRA1 where one allele is mutant for SOX9 and the other is wild type, our study raises the possibility that a high level of SOX9 transactivation activity is normally required for proper testis and bone formation. It is likely that interactions with transcriptional co-activators or components of the basal transcriptional machinery may attenuate the effect of mutation.

    ACKNOWLEDGEMENTS

This work was initiated in the laboratory of Human Molecular Genetics in the department of Genetics at Cambridge University under the supervision of Peter Goodfellow. We thank Peter Fuller and Michael Clarkson for helpful discussion.

    FOOTNOTES

* This work was supported by National Health and Medical Research Council of Australia Grant 983001.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

c Both authors contributed equally to this work.

j To whom correspondence should be addressed. Tel.: 613 9549 3244; Fax: 613 9594 6125; E-mail: vincent.harley@med.monash.edu.au.

Published, JBC Papers in Press, April 25, 2001, DOI 10.1074/jbc.M101278200

2 S. Layfield, D. A. Jans, and V. R. Harley, manuscript in preparation.

3 C. Mitchell and V. R. Harley, unpublished results.

    ABBREVIATIONS

The abbreviations used are: CD/SRA1 campomelic dysplasia/autosomal sex reversal, CAT, chloramphenicol acetyltransferase; HMG, high mobility group; SRY, sex determining region of the Y chromosome; SSCP, single strand conformation polymorphism; WT, wild type; ELISA, enzyme-linked immunosorbent assay; PBS, phosphate-buffered saline; GST, glutathione S-transferase; PAGE, polyacrylamide gel electrophoresis; NLS, nuclear localization signal; HA, hemagglutinin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Foster, J. W., Dominguez-Steglich, M. A., Guioli, S., Kowk, G., Weller, P. A., Stevanovic, M., Weissenbach, J., Mansour, S., Young, I. D., Goodfellow, P. N., Brook, D. N., and Schafer, A. S. (1994) Nature 372, 525-530
2. Wagner, T., Wirth, J., Meyer, J., Zabel, B., Held, M., Zimmer, J., Pasantes, J., Bricarelli, F. D., Keutel, J., Hustert, E., Wolf, U., Tommerup, N., Schempp, W., and Scherer, G. (1994) Cell 79, 1111-1120
3. Lynch, S. A., Gaunt, M. L., and Minford, A. M. (1993) J. Med. Genet. 30, 683-686
4. Schafer, A. J. (2001) in Campomelic Dysplasia/Autosomal Sex Reversal/SOX9 (Scriver , Beaudet , Valle , and Sly, eds), 8th Ed. , McGraw-Hill Inc., New York
5. Cameron, F. J., and Sinclair, A. H. (1997) Hum. Mutat. 9, 388-395
6. Koopman, P. (1999) Cell. Mol. Life Sci. 55, 839-856
7. Harley, V. R., Jackson, D. I., Hextall, P. J., Hawkins, J. R., Berkovitz, G. D., Sockanathan, S., Lovell-Badge, R., and Goodfellow, P. N. (1992) Science 255, 453-456
8. Pontiggia, A., Rimini, R., Harley, V. R., Goodfellow, P. N., Lovell-Badge, R., and Bianchi, M. E. (1994) EMBO J. 13, 6115-6124
9. Morais da Silva, S., Hacker, A., Harley, V., Goodfellow, P., Swain, A., and Lovell-Badge, R. (1996) Nat. Genet. 14, 62-68
10. Kent, J., Wheatley, S. C., Andrews, J. E., Sinclair, A. H., and Koopman, P. (1996) Development 122, 2813-2822
11. de Santa Barbara, P., Moniot, B., Poulat, F., and Berta, P. (2000) Dev. Dyn. 217, 293-298
12. de Santa Barbara, P., Bonneaud, N., Boizet, B., Desclozeaux, M., Moniot, B., Sudbeck, P., Scherer, G., Poulat, F., and Berta, P. (1998) Mol. Cell. Biol. 18, 6653-6665
13. Arango, N. A., Lovell-Badge, R., and Behringer, R. R. (1999) Cell 99, 409-419
14. Ng, L. J., Wheatley, S., Muscat, G. E., Conway-Campbell, J., Bowles, J., Wright, E., Bell, D. M., Tam, P. P., Cheah, K. S., and Koopman, P. (1997) Dev. Biol. 183, 108-121
15. Lefebvre, V., Huang, W., Harley, V. R., Goodfellow, P. N., and de Crombrugghe, B. (1997) Mol. Cell. Biol. 17, 2336-2346
16. Bi, W., Deng, J. M., Zhang, Z., Behringer, R. R., and de Crombrugghe, B. (1999) Nat. Genet. 22, 85-89
17. Lefebvre, V., and DeCrombrugghe, B. (1998) Matrix Biol. 16, 529-540
18. Lefebvre, V., Li, P., and de Crombrugghe, B. (1998) EMBO J. 17, 5718-5733
19. Zhao, Q., Eberspaecher, H., Lefebvre, V., and de Crombrugghe, B. (1997) Dev. Dyn. 209, 377-386
20. Bell, D. M., Leung, K. K., Wheatley, S. C., Ng, L. J., Zhou, S., Ling, K. W., Sham, M. H., Koopman, P., Tam, P. P., and Cheah, K. S. (1997) Nat. Genet. 16, 174-178
21. Sekiya, I., Tsuji, K., Koopman, P., Watanabe, H., Yamada, Y., Shinomiya, K., Nifuji, A., and Noda, M. (2000) J. Biol. Chem. 275, 10738-10744
22. Bridgewater, L. C., Lefebvre, V., and DeCrombrugghe, B. (1998) J. Biol. Chem. 273, 14998-15006
23. Meyer, J., Sudbeck, P., Held, M., Wagner, T., Schmitz, M. L., Bricarelli, F. D., Eggermont, E., Friedrich, U., Haas, O. A., Kobelt, A., Leroy, J. G., Van Maldergem, L., Michel, E., Mitulla, B., Pfeiffer, R. A., Schinzel, A., Schmidt, H., and Scherer, G. (1997) Hum. Mol. Genet. 6, 91-98
24. Kwok, C., Weller, P. A., Guioli, S., Foster, J. W., Mansour, S., Zuffardi, O., Punnett, H. H., Dominguez Steglich, M. A., Brook, J. D., and Young, I. D. (1995) Am. J. Hum. Genet. 57, 1028-1036
25. Foster, J. W. (1996) Acta Paediatr. Jpn. 38, 405-411
26. Hageman, R. M., Cameron, F. J., and Sinclair, A. H. (1998) Hum. Mutat. (suppl.), 112-113
27. McDowall, S., Argentaro, A., Ranganathan, S., Weller, P., Mertin, S., Mansour, S., Tolmie, J., and Harley, V. (1999) J. Biol. Chem. 274, 24023-24030
28. Sudbeck, P., and Scherer, G. (1997) J. Biol. Chem. 272, 27848-27852
29. Mertin, S., McDowall, S. G., and Harley, V. R. (1999) Nucleic Acids Res. 27, 1359-1364
30. Clayton, A. H., and Sawyer, W. H. (1999) Biophys. J. 76, 3235-3242
31. Harley, V. R., Lovell-Badge, R., Goodfellow, P. N., and Hextall, P. J. (1996) FEBS Lett. 391, 24-28
32. Eftink, M. R., and Ghiron, C. A. (1976) Biochemistry 15, 672-680
33. Gauss, G. H., and Lieber, M. R. (1992) Nucleic Acids Res. 20, 6739-6740
34. Hubner, S., Xiao, C. Y., and Jans, D. A. (1997) J. Biol. Chem. 272, 17191-17195
35. van de Wetering, M., Oosterwegel, M., Dooijes, D., and Clevers, H. (1991) EMBO J. 10, 123-132
36. Kim, J., Zwieb, C., Wu, C., and Adhya, S. (1989) Gene (Amst.) 85, 15-23
37. Thompson, J. F., and Landy, A. (1988) Nucleic Acids Res. 16, 9687-9705
38. Jans, D. A., Xiao, C-Y., and Lam, M. H. C. (2000) Bioessays 22, 532-544
39. Vlassi, M., Cesareni, G., and Kokkinidis, M. (1999) J. Mol. Biol. 285, 817-827
40. Hunter, C. A., Singh, J., and Thornton, J. M. (1991) J. Mol. Biol. 218, 837-846
41. Serrano, L., Bycroft, M., and Fersht, A. R. (1991) J. Mol. Biol. 218, 465-475
42. Jasanoff, A., Kochoyan, M., Fraenkel, E., Lee, J. P., and Weiss, M. A. (1992) J. Mol. Biol. 225, 1035-1047
43. Nanda, V., and Brand, L. (2000) Proteins 40, 112-125
44. Padmanabhan, S., and Baldwin, R. L. (1994) Protein Sci. 3, 1992-1997
45. Crane Robinson, C., Read, C. M., Cary, P. D., Driscoll, P. C., Dragan, A. I., and Privalov, P. L. (1998) J. Mol. Biol. 281, 705-717
46. Vijayakumar, M., Qian, H., and Zhou, H. X. (1999) Proteins 34, 497-507
47. Ballesteros, J. A., Deupi, X., Olivella, M., Haaksma, E. E., and Pardo, L. (2000) Biophys. J. 79, 2754-2760
48. Zeng, Y. T., Ren, Z. R., Zhang, M. L., Huang, Y., Zeng, F. Y., and Huang, S. Z. (1993) J. Med. Genet. 30, 655-657
49. Jager, R. J., Harley, V. R., Pfeiffer, R. A., Goodfellow, P. N., and Scherer, G. (1992) Hum. Genet. 90, 350-355
50. Ferrari, S., Harley, V. R., Pontiggia, A., Goodfellow, P. N., Lovell-Badge, R., and Bianchi, M. E. (1992) EMBO J. 11, 4497-4506
51. Giese, K., Pagel, J., and Grosschedl, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3368-3372
52. Deckert, J., Khalaf, R. A., Hwang, S. M., and Zitomer, R. S. (1999) Nucleic Acids Res. 27, 3518-326


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea